Compositions that specifically bind to colorectal cancer cells and methods of using the same

• US 7,316,902 B2
• Filed: 09/05/2003
• Issued: 01/08/2008
• Est. Priority Date: 08/07/1997
• Status: Expired due to Fees

• Current Assignee: Thomas Jefferson University (Main Line Health System)
• Original Assignee: Thomas Jefferson University (Main Line Health System)
• Inventors: Barber, Michael T., Parkinson, Scott J., Pearlman, Joshua M., Waldman, Scott A., Schulz, Stephanie
• Primary Examiner(s): Rawlings; Stephen L.
• Application Number:
  US10/656,895
• Publication Number:
  US 20040146954A1
• Time in Patent Office: 1,586 Days
• Field of Search: 435/6, 435/91.2, 536/23.5, 536/24.33, 536/24.31, 436/64
• US Class Current: 435/6.14
• CPC Class Codes: A61K 2039/51 comprising whole cells, viruses or DNA/RNA
• CPC Class Codes: A61K 39/00 Medicinal preparations containing antigens or antibodies materials for immunoassay G01N33/53
• CPC Class Codes: C07K 14/705 Receptors; Cell surface antigens; Cell surface determinants tumour specific antigens C07K14/4748
• CPC Class Codes: C07K 2319/00 Fusion polypeptide
• CPC Class Codes: G01N 33/57419 of colon

Abstract

A unique transcription product, CRCA-1, and alternative translation products generated therefrom, are disclosed. The transcript and its translation products are markers for colorectal cells. Screening and diagnostic reagents, kits and methods for metastasized colorectal cancer are disclosed ars are reagents, kits and methods for identifying adenocarcinomas as colorectal in origin. Compounds, compositions and methods of treating patients with metastasized colorectal cancer and for imaging metastasized colorectal tumors in vivo are disclosed. Compositions and methods for delivering active compounds such as gene therapeutics and antisense compounds to colorectal cells are disclosed. Vaccines compositions and methods of for treating and preventing metastasized colorectal cancer are disclosed.

Claims

1. An in vitro method of determining whether or not an individual has metastasized colorectal cancer cells comprising the steps of examining a sample of lymph node tissue from an individual to determine whether CRCA-1 mRNA is present in said sample wherein the presence of said CRCA-1 mRNA is indicative of the presence of metastasized colorectal cancer cells in said sample, wherein said CRCA-1 mRNA comprises the ribonucleotide sequence corresponding to the deoxyribonucleotide sequence of the complementary DNA (cDNA) molecule of SEQ ID NO:

1, which was generated from said mRNA.

2. The method of claim 1 wherein the presence of said CRCA-1 mRNA in said sample is determined by polymerase chain reaction wherein said sample is contacted with primers that selectively amplify said CRCA-1 mRNA or cDNA generated therefrom.